Paper8286205
Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.
Seymour MT and 7 others. Br J Cancer, 1994. Cited by 61 papers, by iCite.
Cite this record
ConductScience Library. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Papers, record 8286205. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8286205
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carboplatin | Major topic |
| Cisplatin | Major topic |
| Etoposide | Major topic |
| Ovarian Neoplasms | Major topic |
| Administration, Oral | |
| Adult | |
| Aged | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Drug Resistance | |
| Epithelium | |
| Female | |
| Humans | |
| Middle Aged | |
| Prospective Studies |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7340985 | A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/7340985 | PubMed |
| 2 | 4054715 | Phase II trial of VP-16-213 in advanced ovarian carcinoma. | Gynecol Oncol | 1985 | https://conductscience.org/library/papers/4054715 | PubMed |
| 3 | 3000790 | Variable bioavailability following repeated oral doses of etoposide. | Eur J Cancer Clin Oncol | 1985 | https://conductscience.org/library/papers/3000790 | PubMed |
| 4 | 3082726 | Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies. | Gynecol Oncol | 1986 | https://conductscience.org/library/papers/3082726 | PubMed |
| 5 | 3102056 | Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. | Cancer Treat Rep | 1987 | https://conductscience.org/library/papers/3102056 | PubMed |
| 6 | 2736711 | A phase II study of mitozantrone in advanced carcinoma of the ovary. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2736711 | PubMed |
| 7 | 2569287 | Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. | Ann Intern Med | 1989 | https://conductscience.org/library/papers/2569287 | PubMed |
| 8 | 2549204 | A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2549204 | PubMed |
| 9 | 2509641 | Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2509641 | PubMed |
| 10 | 2104819 | Hexamethylmelamine as a single second-line agent in ovarian cancer. | Gynecol Oncol | 1990 | https://conductscience.org/library/papers/2104819 | PubMed |
| 11 | 2154858 | Phase II study of daily oral etoposide in refractory germ cell tumors. | Semin Oncol | 1990 | https://conductscience.org/library/papers/2154858 | PubMed |
| 12 | 2154861 | Chronic daily administration of oral etoposide. | Semin Oncol | 1990 | https://conductscience.org/library/papers/2154861 | PubMed |
| 13 | 2318446 | Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer. | Gynecol Oncol | 1990 | https://conductscience.org/library/papers/2318446 | PubMed |
| 14 | 2195412 | Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study. | Oncology | 1990 | https://conductscience.org/library/papers/2195412 | PubMed |
| 15 | 1694980 | Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy. | Oncology | 1990 | https://conductscience.org/library/papers/1694980 | PubMed |
| 16 | 2170588 | Low-dose oral etoposide: a new role for an old drug? | J Clin Oncol | 1990 | https://conductscience.org/library/papers/2170588 | PubMed |
| 17 | 2145914 | Epirubicin for pretreated advanced ovarian cancer. | Eur J Cancer | 1990 | https://conductscience.org/library/papers/2145914 | PubMed |
| 18 | 1357110 | Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. | J Clin Oncol | 1992 | https://conductscience.org/library/papers/1357110 | PubMed |
| 19 | 8382514 | Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8382514 | PubMed |
| 20 | 8353095 | Low-dose oral etoposide in epithelial cancer of the ovary. | Ann Oncol | 1993 | https://conductscience.org/library/papers/8353095 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 27099605 | Patients with Advanced Ovarian Cancer Administered Oral Etoposide following Taxane as Maintenance Chemotherapy. | Case Rep Oncol | 2016 | https://conductscience.org/library/papers/27099605 | PubMed |
| 22045509 | Recurrent ovarian cancer: when and how to treat. | Curr Oncol Rep | 2011 | https://conductscience.org/library/papers/22045509 | PubMed |
| 20480200 | Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer. | Int J Clin Oncol | 2010 | https://conductscience.org/library/papers/20480200 | PubMed |
| 15956976 | Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. | Br J Cancer | 2005 | https://conductscience.org/library/papers/15956976 | PubMed |
| 15756278 | Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer. | Br J Cancer | 2005 | https://conductscience.org/library/papers/15756278 | PubMed |
| 12875610 | Pharmacological factors influencing anticancer drug selection in the elderly. | Drugs Aging | 2003 | https://conductscience.org/library/papers/12875610 | PubMed |
| 11857002 | Weekly platinum chemotherapy for recurrent ovarian cancer. | Br J Cancer | 2002 | https://conductscience.org/library/papers/11857002 | PubMed |
| 11122800 | Salvage therapy for ovarian cancer. | Curr Oncol Rep | 1999 | https://conductscience.org/library/papers/11122800 | PubMed |
| 10933513 | Drug therapy for gynaecological cancer in older women. | Drugs Aging | 2000 | https://conductscience.org/library/papers/10933513 | PubMed |
| 10711841 | Oral etoposide for the treatment of recurrent ovarian cancer. | Drugs | 1999 | https://conductscience.org/library/papers/10711841 | PubMed |
| 7497587 | Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7497587 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MUC16 | 94025 | PubTator's text mining | https://conductscience.org/library/genes/94025 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8286205
GET https://conductscience.org/api/papers/v1/8286205/authors